{"id":2615,"date":"2018-12-01T12:03:00","date_gmt":"2018-12-01T11:03:00","guid":{"rendered":"https:\/\/der-arzneimittelbrief.com\/artikel\/2018\/rivaroxaban-zur-antikoagulation-nach-tavi-ungeeignet"},"modified":"2018-12-01T12:03:00","modified_gmt":"2018-12-01T11:03:00","slug":"rivaroxaban-zur-antikoagulation-nach-tavi-ungeeignet","status":"publish","type":"post","link":"https:\/\/der-arzneimittelbrief.com\/artikel\/2018\/rivaroxaban-zur-antikoagulation-nach-tavi-ungeeignet","title":{"rendered":"Rivaroxaban zur Antikoagulation nach TAVI ungeeignet"},"content":{"rendered":"<p>Zur antithrombotischen Therapie nach katheterinterventionellem Aortenklappen-Ersatz (TAVI) wird in der aktuellen Leitlinie der European Society of Cardiology bei niedrigem Blutungsrisiko eine duale Pl\u00e4ttchenhemmung (ASS plus Clopidogrel) \u00fcber drei bis sechs Monate empfohlen, gefolgt von einer pl\u00e4ttchenhemmenden Monotherapie (Empfehlungsklasse IIa; 1, vgl. 2). Bei erh\u00f6htem Blutungsrisiko kann von Anfang an eine Monotherapie erwogen werden (Empfehlungsklasse IIb). [&hellip;]<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Zur antithrombotischen Therapie nach katheterinterventionellem Aortenklappen-Ersatz (TAVI) wird in der aktuellen Leitlinie der European Society of Cardiology bei niedrigem Blutungsrisiko eine duale Pl\u00e4ttchenhemmung (ASS plus Clopidogrel) \u00fcber drei bis sechs Monate empfohlen, gefolgt von einer pl\u00e4ttchenhemmenden Monotherapie (Empfehlungsklasse IIa; 1, vgl. 2). Bei erh\u00f6htem Blutungsrisiko kann von Anfang an eine Monotherapie erwogen werden (Empfehlungsklasse IIb). [&hellip;]<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[1],"tags":[137,2778,4593,2678,2777,4592,2676,1314,1312,5140,1328,1327,2304,2775,2776],"class_list":["post-2615","post","type-post","status-publish","format-standard","hentry","category-allgemein","tag-antikoagulanzien","tag-aortenklappen-ersatz","tag-aortenklappen-insuffizienz","tag-aortenklappen-stenose","tag-aortenklappenersatz","tag-aortenklappeninsuffizienz","tag-aortenstenose","tag-direkte-orale-antikoagulanzien","tag-doak","tag-galileo-studie","tag-neue-orale-antikoagulanzien","tag-noak","tag-rivaroxaban","tag-tavi","tag-transcatheter-aortic-valve-implantation"],"_links":{"self":[{"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/posts\/2615","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/comments?post=2615"}],"version-history":[{"count":0,"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/posts\/2615\/revisions"}],"wp:attachment":[{"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/media?parent=2615"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/categories?post=2615"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/tags?post=2615"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}